Loading...
Protection of Hamsters Challenged with SARS-CoV-2 Variants of Concern by Two Doses of MVC-COV1901 Vaccine Followed by a Single Dose of Beta Variant Version of MVC-COV1901
Kuo, Tsun-Yung Lien, Chia-En Lin, Yi-Jiun Lin, Meei-Yun Wu, Chung-Chin Tang, Wei-Hsuan Campbell, John D. Traquina, Paula Chuang, Ya-Shan Liu, Luke Tzu-Chi
Kuo, Tsun-Yung
Lien, Chia-En
Lin, Yi-Jiun
Lin, Meei-Yun
Wu, Chung-Chin
Tang, Wei-Hsuan
Campbell, John D.
Traquina, Paula
Chuang, Ya-Shan
Liu, Luke Tzu-Chi
Citations
Altmetric:
Genre
Pre-print
Date
2022-01-06
Advisor
Committee member
Group
Department
Biology
Subject
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1101/2021.09.29.462344
Abstract
The current fight against COVID-19 is compounded by the Variants of Concern (VoCs), which can diminish the effectiveness of vaccines and potentially increase viral transmission and severity of disease. MVC-COV1901 is a protein subunit vaccine based on the prefusion SARS-CoV-2 spike protein (S-2P) and is adjuvanted with CpG 1018 and aluminum hydroxide. In this study, we used the Delta variant to challenge hamsters inoculated with S-2P from the Wuhan wildtype and the Beta variant in two-dose or three-dose regimens. Two doses of wildtype S-2P followed by the third dose of Beta variant was shown to induce the highest neutralizing antibody titer against live SARS-CoV-2 of the wildtype and all current VoCs, as well as improved neutralization against Omicron variant pseudovirus compared to three doses of wildtype S-P. All regimens of vaccination were able to protect hamsters from SARS-CoV-2 Delta variant challenge and resulted in reduced lung live virus titer and pathology. Three doses of vaccination also significantly reduced lung viral RNA titer, regardless of whether the wildtype or Beta variant S-2P was used as the third dose. Based on the immunogenicity and viral challenge data, two doses of wildtype S-2P followed by the third dose of Beta variant S-2P induced potent antibody immune responses against the VoCs.
Description
Citation
Citation to related work
bioRxiv
Has part
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu